Minnesota § 151.361 MANUFACTURER DISCLOSURE

Minnesota Statutes

§ 151.361 — MANUFACTURER DISCLOSURE

Minnesota § 151.361

PartHEALTH

Ch. 151PHARMACY PRACTICE AND WHOLESALE DISTRIBUTION ACT

This text of Minnesota § 151.361 (MANUFACTURER DISCLOSURE) is published on Counsel Stack Legal Research, covering Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Minn. Stat. § 151.361 (2026).

Text

Subdivision 1.After January 1, 1976. The manufacturer, packager, or distributor of any human use legend drug sold, delivered, or offered for sale in the state of Minnesota after January 1, 1976 must have printed on the label on the immediate container of the drug the name and address of the manufacturer of the finished dosage form of the drug. Subd. 2.After January 1, 1983.

(a)No legend drug in solid oral dosage form may be manufactured, packaged or distributed for sale in this state after January 1, 1983 unless it is clearly marked or imprinted with a symbol, number, company name, words, letters, national drug code or other mark uniquely identifiable to that drug product. An identifying mark or imprint made as required by federal law or by the federal Food and Drug Administration shall

Free access — add to your briefcase to read the full text and ask questions with AI

Subdivision 1.After January 1, 1976.
The manufacturer, packager, or distributor of any human use legend drug sold, delivered, or offered for sale in the state of Minnesota after January 1, 1976 must have printed on the label on the immediate container of the drug the name and address of the manufacturer of the finished dosage form of the drug.

Subd. 2.After January 1, 1983.
(a) No legend drug in solid oral dosage form may be manufactured, packaged or distributed for sale in this state after January 1, 1983 unless it is clearly marked or imprinted with a symbol, number, company name, words, letters, national drug code or other mark uniquely identifiable to that drug product. An identifying mark or imprint made as required by federal law or by the federal Food and Drug Administration shall be deemed to be in compliance with this section.
(b) The Board of Pharmacy may grant exemptions from the requirements of this section on its own initiative or upon application of a manufacturer, packager, or distributor indicating size or other characteristics that render the product impractical for the imprinting required by this section.

Subd. 3.Penalty.
Failure to comply with the requirements of this section shall subject a drug to embargo in accordance with section151.38.